These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21129274)

  • 1. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
    Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
    Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
    Oboshi W; Watanabe T; Matsuyama Y; Kobara A; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
    Hum Immunol; 2016 Feb; 77(2):165-71. PubMed ID: 26582002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
    Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
    Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
    Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
    BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
    Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
    J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fcγ receptorIIIa polymorphism in healthy children and those with hematological malignancies].
    Qu YH; Li Y; Wu YF; Fang JP; Wei J; Huang SL; Ma XX; Huang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):959-62. PubMed ID: 20723308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
    Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
    Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
    J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.
    Talathi SP; Shaikh NN; Pandey SS; Saxena VA; Mamulwar MS; Thakar MR
    BMC Infect Dis; 2019 Dec; 19(1):1053. PubMed ID: 31842762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.
    Mishima Y; Terui Y; Mishima Y; Kuniyoshi R; Matsusaka S; Mikuniya M; Kojima K; Hatake K
    Int Immunol; 2012 Aug; 24(8):477-83. PubMed ID: 22438420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells.
    Li Y; Huang K; Liu L; Qu Y; Huang Y; Wu Y; Wei J
    Oncol Lett; 2019 Jan; 17(1):339-347. PubMed ID: 30655772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
    Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
    Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
    Terszowski G; Klein C; Stern M
    J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
    Trotta AM; Ottaiano A; Romano C; Nasti G; Nappi A; De Divitiis C; Napolitano M; Zanotta S; Casaretti R; D'Alterio C; Avallone A; Califano D; Iaffaioli RV; Scala S
    Cancer Immunol Res; 2016 Apr; 4(4):366-74. PubMed ID: 26817995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.